Drug Trial Radar · NCT07912996
Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to compare the study drug GS-1179, versus valacyclovir (VACV) in herpes simplex virus type 2 (HSV-2) seropositive participants with recurrent genital herpes. The primary objective of this study are to evaluate the safety and tolerability of GS-1179 versus VACV and to evaluate the antiviral effect of GS-1179 versus VACV.
Conditions
- HSV-2 Infection
Interventions
GS-1179Drug
Administered orally
GS-1179 PTMDrug
Administered orally
ValacyclovirDrug
Administered orally
Valacyclovir PTMDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Adverse Events (AEs)Time frame: Enrollment up to 92 days
- Percentage of Participants Experiencing Premature Study-Dug Discontinuation due to AEsTime frame: Enrollment up to 92 days
- Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose date up to 92 days
- Herpes Simplex Virus Type 2 (HSV-2) Shedding Rate During the Swabbing PeriodTime frame: Day 8 to Day 38
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.